Evidence Supports Adding Biological, Pathological, and Molecular Assessments to the TNM Lung Cancer Staging System
Beth Fand IncollingoA presentation at the 2022 European Lung Cancer Congress convinced attendees that the current system for staging lung cancer needs refinement. Read more
A real-world look at diagnostic-therapeutic pathways explores how they may help provide optimal, innovative care without ballooning costs. Read more
Small, High PLCG2-Expressing Intratumoral Cells May Drive Metastasis
Alvaro Quintanal-Villalonga, PhD+more
In the search to understand the mechanisms of metastasis, researchers have expanded the spectrum of SCLC clinical specimens amenable for single-cell resolution analysis. Read more
COAST Data Support Further Research of Immunotherapy Combinations
Mariona Riudavets, MD, PhD+more
Trial is the first to show improved efficacy and a manageable safety profile after cCRT in unresectable locally advanced stage III NSCLC regardless of PD-L1 status. Read more
TIL Therapy Endures for Carefully Selected Patients: A Q&A with Dr. Benjamin C. Creelan
Joy CurzioDr. Benjamin C. Creelan shares his passion for cell therapy research and insights into current data. Read more
Early Palliative Care: A European Perspective
Florian Scotté, MD, PhDThe benefits of early palliative care have been proven. Could negative connotations of palliative care be impeding its adoption? Read more
Tumor Growth Rate as a Guide for Precision Lung Cancer Therapy
Mizuki Nishino, MD, MPH+more
The speed at which a tumor progresses may prove to be a useful tool in therapeutic decision-making. Read more
Patient Perspective: The Promise of Personalized Medicine
Angus Pratt, MBAGrowing treatment options for patients with late-stage lung cancer bring hope—and challenges. Read more
Cancer Misinformation: Its Impact on Patients and Mitigation Strategies
Skyler B. Johnson, MDInaccurate health information can have grave consequences, but there are techniques providers can use to combat it. Read more
A Look at Veliparib Plus Chemotherapy for First-Line Treatment of Advanced NSCLC
Ticiana Leal, MD+more
The strategy likely will not be pursued, however studies of PARP inhibitors plus immune checkpoint inhibitors are already in advanced stages. Read more